Cargando…

Which is the optimal adjuvant chemotherapy for resected pancreatic ductal adenocarcinoma?: A protocol for a network meta-analysis of randomized controlled trials

BACKGROUND: Although adjuvant chemotherapy has been shown to reduce relapse and prolong survival after surgery, it is still unclear which adjuvant chemotherapy regimen will be favorable over the all adjuvant treatments evaluated for patients with resected pancreatic ductal adenocarcinoma. METHODS: P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Qiancheng, Wang, Xin, Chen, Ye, Li, Xiaofen, Cao, Peng, Cao, Dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6571414/ https://www.ncbi.nlm.nih.gov/pubmed/31124963 http://dx.doi.org/10.1097/MD.0000000000015761

Ejemplares similares

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
por: Hu, Qiancheng, et al.
Publicado: (2019)

Comparative efficacy and safety of neoadjuvant radiotherapy for patients with borderline resectable, and locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis protocol
por: Lv, Wanrui, et al.
Publicado: (2022)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

Adjuvant Chemotherapy and Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Clinical Practice Guideline
por: Biagi, James J., et al.
Publicado: (2023)

Optimal adjuvant chemotherapy for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis
por: Xu, Jian-Bo, et al.
Publicado: (2017)

Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma
por: Iyengar, Siddharth, et al.
Publicado: (2021)

Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials
por: Hu, Qiancheng, et al.
Publicado: (2020)

Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
por: Cao, Ying-Ying, et al.
Publicado: (2023)

Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data
por: Chikhladze, Sophia, et al.
Publicado: (2019)

An EMT-Related Gene Signature for Predicting Response to Adjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma
por: Feng, Zengyu, et al.
Publicado: (2021)

A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
por: Chang, Chen, et al.
Publicado: (2022)

Optimal dose-fractionation schedule of palliative radiotherapy for patients with bone metastases: a protocol for systematic review and network meta-analysis
por: Tang, Xiaofang, et al.
Publicado: (2020)

Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma
por: Li, Bo, et al.
Publicado: (2021)

Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
por: Mortier, Victor, et al.
Publicado: (2022)

Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study
por: Chang, Chen, et al.
Publicado: (2021)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Feasibility of delivering supervised exercise training following surgical resection and during adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PRECISE): a case series
por: Brown, Malcolm, et al.
Publicado: (2023)

Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma
por: Wysocka, Olga, et al.
Publicado: (2016)

Clarifying the role of adjuvant therapy after multi-agent neoadjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma
por: Lan, Xiaoyang, et al.
Publicado: (2023)

Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma
por: Ormanns, Steffen, et al.
Publicado: (2015)

Pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head with venous resection
por: Flis, Vojko, et al.
Publicado: (2016)

Contemporary management of borderline resectable pancreatic ductal adenocarcinoma
por: Lekka, Kyriaki, et al.
Publicado: (2019)

Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma
por: Bonds, Morgan, et al.
Publicado: (2019)

Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
por: Acuna-Villaorduna, Ana, et al.
Publicado: (2022)

Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate‐adjusted analysis at the pre‐adjuvant chemotherapy timing
por: Fu, Ningzhen, et al.
Publicado: (2022)

Pancreatic ductal adenocarcinoma: Role of chemotherapy & future perspectives
por: Tiwari, Akash, et al.
Publicado: (2018)

Potential prognostic biomarkers in pancreatic juice of resectable pancreatic ductal adenocarcinoma
por: Agrawal, Shefali
Publicado: (2017)

The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma
por: Ma, Heng, et al.
Publicado: (2023)

Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX
por: Lee, So Heun, et al.
Publicado: (2023)

Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
por: Buc, Emmanuel, et al.
Publicado: (2014)

An Evaluation of Neoadjuvant Chemoradiotherapy for Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Jiang, Hui, et al.
Publicado: (2013)

Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma
por: Lohneis, Philipp, et al.
Publicado: (2018)

The borderline resectable and locally advanced pancreatic ductal adenocarcinoma: Definition
por: Soweid, Assaad M.
Publicado: (2017)

Stromal fibronectin expression in patients with resected pancreatic ductal adenocarcinoma
por: Hu, Dingyuan, et al.
Publicado: (2019)

Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection
por: Sugawara, Toshitaka, et al.
Publicado: (2021)

Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study
por: Kamarajah, Sivesh K., et al.
Publicado: (2021)

Survival benefit and impact of adjuvant chemotherapy following systemic neoadjuvant chemotherapy in patients with resected pancreas ductal adenocarcinoma: a retrospective cohort study
por: Pu, Ning, et al.
Publicado: (2023)

Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma
por: Chen, Ru, et al.
Publicado: (2014)

The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma
por: Kawahara, Kenji, et al.
Publicado: (2022)

Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
por: Shui, Lin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0sgj670qrsd9tonp9fjgsgpebn